Re: ADAM-17: A potential therapeutic target to prevent organ injury after hemorrhagic shock?
- PMID: 28234663
- PMCID: PMC5400708
- DOI: 10.1097/TA.0000000000001397
Re: ADAM-17: A potential therapeutic target to prevent organ injury after hemorrhagic shock?
Conflict of interest statement
The author declares no conflict of interest
The author has nothing to disclose
Comment on
-
Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock.J Trauma Acute Care Surg. 2016 Aug;81(2):358-65. doi: 10.1097/TA.0000000000001056. J Trauma Acute Care Surg. 2016. PMID: 27027557 Free PMC article.
-
ADAM-17: A potential therapeutic target to prevent organ injury after hemorrhagic shock?J Trauma Acute Care Surg. 2017 May;82(5):976. doi: 10.1097/TA.0000000000001396. J Trauma Acute Care Surg. 2017. PMID: 28234662 No abstract available.
References
-
- Cesaro A, Abakar-Mohamat A, Brest P, et al. Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. Am J Physiol Gastrointest Liver Physiol. 2009;296(6):G1332–43. - PubMed
-
- Dreymueller D, Uhlig S, Ludwig A. ADAM-family metalloproteinases in lung inflammation: potential therapeutic targets. Am J Physiol Lung Cell Mol Physiol. 2015;308(4):L325–L343. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
